Press releases

Cronos Grows its International Footprint in Switzerland

Cronos Group announced today that it is expanding distribution with its PEACE NATURALS® medical cannabis brand in the Swiss market through its partnership with Dascoli Pharma AG (“Dascoli”), a Swiss-based company specializing in the supply and distribution of medical cannabis and healthcare training.

Following its launch in three new countries in 2025, Green Success 1.0 is now live in Germany, the UK, Australia, and the Czech Republic.

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it is expanding distribution with its PEACE NATURALS® medical cannabis brand in the Swiss market through its partnership with Dascoli Pharma AG (“Dascoli”), a Swiss-based company specializing in the supply and distribution of medical cannabis and healthcare training.

“We are excited to partner with Dascoli to bring high-quality medical cannabis to Swiss patients,” said Mike Gorenstein, Chairman, President and CEO, Cronos. “This partnership aligns with our mission to provide borderless cannabis products to European medical markets. Expanding our presence in Europe is an important area of focus for Cronos’ growth, and through this collaboration, we will leverage Dascoli’s strong local presence to better serve the needs of patients.”

Under the agreement, Cronos will supply PEACE NATURALS®-branded cannabis flower to Dascoli for distribution across its established medical network in Switzerland. This strategic collaboration marks another step in Cronos’ international growth strategy and strengthens its presence in key emerging medical cannabis markets.

The following PEACE NATURALS® flower will be available:

  • GMO Cookies
  • Space Cake
  • Atomic Sour Grapefruit
  • Sonic Lemon Fuel
  • Wedding Cake

PEACE NATURALS® medical cannabis products also recently launched in Australia and Malta. The brand is now available for patients in Australia, Canada, Germany, Israel, Malta, Switzerland and the UK.

Topicscronos groupDascoliDascoli Pharma AGswitzerland

Ben Stevens

Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.

More from Ben

Spotted an error, or have a tip? Contact the newsroom.

Up next · Press releases

Grow Group Completes £12m Recapitalisation and Restructuring, Appoints Co-CEOs and Completes Transition to Full Operations at its UK Manufacturing Facility

BusinessOfCannabis · 11 November 2026

More